メインコンテンツへスキップ
見出し画像

CRP Is a Delayed Inflammatory Readout: IL-6, Kinetics, and the Limits of a Single Biomarker

    CRP is a downstream hepatic response rather than a direct measure of inflammatory cause. This article connects IL-6-driven acute-phase signaling with CRP kinetics, nonspecificity, population modifiers, and the need for context-aware biomarker interpretation.

    CRP is routinely used to assess systemic inflammation, yet a measured CRP concentration is separated in both biology and time from the inflammatory signals that initiate the response. Understanding that separation is essential when interpreting CRP across infection, cardiovascular disease, chronic inflammatory states, and changing clinical conditions.

    This article examines CRP as a delayed downstream output of IL-6-driven hepatic signaling, with particular attention to kinetics, etiological nonspecificity, population modifiers, and the limits of interpreting a single measurement in isolation.

    From IL-6 Signaling to Hepatic CRP Production

    IL-6 Is Upstream; CRP Is Downstream

    Interleukin-6 (IL-6), produced in response to inflammation and tissue injury, is a major cytokine that acts on hepatocytes to induce acute-phase proteins including C-reactive protein (CRP). CRP is therefore one downstream output of an IL-6-dependent hepatic acute-phase program rather than an upstream inflammatory signal [Tanaka et al., 2014; Castell et al., 1989; Sproston and Ashworth, 2018].

    That biological ordering matters beyond the liver. In atherosclerotic cardiovascular disease, IL-6 and CRP have been investigated as biomarkers of residual inflammatory risk and future cardiovascular events, while upstream inflammatory signaling involving IL-6 contributes to the biology of atherosclerotic lesions [Ridker, 2016; Ridker et al., 2020; Mehta et al., 2025; Tanaka et al., 2014].

    Why CRP Matters Across Cardiovascular and Acute Inflammatory Settings

    CRP is widely used as an indicator of inflammatory state. In cardiovascular research, IL-6 and high-sensitivity CRP (hsCRP) have been studied as biomarkers of residual inflammatory risk; during the COVID-19 pandemic, circulating IL-6 and CRP were also repeatedly associated with disease severity [Sproston and Ashworth, 2018; Ridker et al., 2020; Zeng et al., 2020].

    In cardiovascular risk assessment, hsCRP has been extensively studied as an inflammatory biomarker for future event prediction and stratification. Biologically, however, CRP remains a hepatic acute-phase protein whose production is induced by inflammatory cytokines, with IL-6 as a major regulator [Ridker, 2007; Ridker et al., 2000; Sproston and Ashworth, 2018; Castell et al., 1989].

    Early COVID-19 studies similarly found associations between IL-6, CRP, disease severity, and outcomes. Those population-level associations made the markers useful for describing systemic inflammation, but did not by themselves establish that either marker—alone or in combination—could serve as a validated stand-alone tool for prognosis or treatment selection [Zeng et al., 2020; Ji et al., 2020; Samprathi and Jayashree, 2021; Bivona et al., 2021].


    Timing Changes the Meaning of CRP

    CRP Rises After the Inflammatory Signal

    IL-6 is a major inducer of hepatic acute-phase protein synthesis, but circulating CRP does not rise immediately after an inflammatory stimulus. After a single stimulus, a detectable rise has been reported from approximately 6 hours, with a peak around 48 hours; in clinical settings such as infection, the rise may begin after 12–24 hours and peak after 2–3 days. These values are approximate and context dependent, but they illustrate the central point: CRP is a delayed hepatic response to upstream inflammatory signaling [Castell et al., 1989; Pepys and Hirschfield, 2003; Sproston and Ashworth, 2018; Markanday, 2015].

    Early Inflammation Can Be Missed by a Single CRP Measurement

    Because that downstream response takes time, a single CRP measurement can underestimate early inflammation when the clinical state is changing rapidly. IL-6 and procalcitonin have different kinetics and diagnostic characteristics, so their results may sometimes provide complementary information; interpretation still depends on clinical history, physical findings, microbiological testing when relevant, and longitudinal changes rather than on one biomarker in isolation [Markanday, 2015; Lee et al., 2022; Tocu et al., 2023; Sproston and Ashworth, 2018].


    Elevated CRP Does Not Reveal a Unique Cause

    One Marker, Many Inflammatory Contexts

    CRP can increase in infection, but also after trauma or surgery and in autoimmune disease, malignancy, obesity, diabetes, and metabolic syndrome-associated low-grade inflammation. It is therefore nonspecific with respect to etiology and cannot identify the cause of inflammation on its own [Markanday, 2015; Singh et al., 2026; Lee et al., 2019; Devaraj et al., 2009].

    Accordingly, similar CRP elevations can arise from biologically distinct inflammatory processes.

    Persistent CRP Elevation and Population Modifiers

    Persistent or recurrent CRP elevation can occur in the setting of chronic inflammatory disease or chronic low-grade inflammation associated with obesity and metabolic dysfunction. Repeated values above 10 mg/L have, for example, been reported particularly in women with obesity. Such observations do not make a high CRP unimportant; they show why a single elevated value should be interpreted against prior values, body composition, sex, metabolic context, medication history, other clinical findings, and serial change [Visser et al., 1999; Ishii et al., 2012; Singh et al., 2026; Devaraj et al., 2009].

    Population characteristics also affect CRP distributions. Age, sex, BMI, pregnancy, and comorbidities can influence CRP values and upper reference limits. In pregnancy, pregnancy-specific reference intervals have been investigated because nonpregnant adult ranges do not necessarily provide the most appropriate context [Wener et al., 2000; Randall et al., 2022; Dockree et al., 2021; Singh et al., 2026].

    Conceptual diagram showing inflammatory stimulus → IL-6 → liver and hepatocytes → CRP production → delayed circulating CRP. Background factors and clinical findings, other tests, and longitudinal changes are shown as important context for interpreting CRP.
    Figure A1. CRP is a delayed downstream readout of inflammatory signaling.
    IL-6 acts upstream of hepatic CRP production, so circulating CRP changes after a biological delay rather than simultaneously with the initiating inflammatory signal. CRP levels and their interpretation can also be influenced by background factors, and a single value should therefore be interpreted together with clinical findings, other tests, and longitudinal change.

    Inflammatory stimuli promote IL-6 signaling, which stimulates hepatic CRP synthesis and secretion. The arrows indicate a conceptual biological sequence rather than a quantitative time course. CRP is nonspecific with respect to etiology, and the figure does not define diagnostic thresholds or identify a cause from an individual CRP value.


    Interpreting CRP in Context

    Practical Strengths and Structural Limits of CRP

    CRP remains useful because it is widely available, relatively inexpensive, and readily repeated over time. These properties make it valuable for following the degree and trajectory of systemic inflammation. Its structural limitations are equally important: it is nonspecific, it cannot localize the source of inflammation, and its delayed kinetics can obscure an early change when a single measurement is considered without context [Singh et al., 2026; Stec-Martyna et al., 2025; MedlinePlus, 2025; Markanday, 2015].

    Why Multi-Biomarker Context Matters

    When one inflammatory marker is insufficient, complementary biomarker approaches can add information. In rheumatoid arthritis, multi-biomarker disease activity panels have incorporated markers including IL-6, serum amyloid A, TNF receptor I, and CRP; serum amyloid A has been investigated across inflammatory rheumatic diseases, and IL-6, soluble IL-6 receptor (sIL-6R), and soluble gp130 (sgp130) have been evaluated in COVID-19-related signaling studies [Centola et al., 2013; Sorić Hosman et al., 2021; Ziegler et al., 2022].

    During tocilizumab therapy, circulating IL-6 may rise, and the correspondence between multi-biomarker disease activity scores and conventional clinical disease-activity measures may change [Reiss et al., 2016]. This illustrates a broader principle: a composite score is not independent of treatment context.

    In infection research, CRP may also be considered alongside clinical findings, microbiological testing, procalcitonin, IL-6, and longitudinal change. In rheumatoid arthritis, multi-biomarker approaches have likewise been developed for disease-activity assessment. The available evidence does not establish one fixed biomarker panel that can be applied across all inflammatory diseases for diagnosis or risk stratification; marker choice and interpretation remain dependent on disease context, clinical purpose, and timing [Markanday, 2015; Hung et al., 2020; Singh et al., 2026; Centola et al., 2013].


    Conclusion: CRP Is a Contextual, Time-Dependent Output

    Across inflammatory disease, cardiovascular disease, and COVID-19, the IL-6–CRP axis is most informative when CRP is treated as a downstream component of a broader inflammatory system rather than a direct readout of cause [Tanaka et al., 2014; Sproston and Ashworth, 2018; Ridker et al., 2020; Zeng et al., 2020].

    The IL-6–CRP relationship therefore explains both the utility and the limitations of CRP. IL-6 is upstream, whereas hepatic CRP is a delayed downstream output whose meaning depends on timing, disease context, patient characteristics, and treatment [Tanaka et al., 2014; Sproston and Ashworth, 2018]. CRP can be highly informative without being etiologically specific, and a single value cannot capture the full architecture of inflammation.

    The companion articles extend this framework in two directions: multilayer measurement of inflammatory signaling, and interpretation of biomarkers under IL-6-targeted therapy.


    Medical Disclaimer

    This article provides general scientific and medical information. It is not intended to interpret individual laboratory results or to provide guidance on diagnosis, drug selection, dosing, treatment initiation, modification, or discontinuation.


    Production Note

    This article was developed with generative-AI assistance for structure, drafting, language editing, and citation and consistency checks. The author reviewed and edited the scientific content, wording, and references and retains responsibility for the final content.

    The figure in this article was produced with generative AI and programmatic drawing assistance. The author reviewed and edited its scientific content, labels, and layout.


    Related Articles


    Work With Rin Kamo

    For science writing, biomedical content development, literature research, or specialist editorial support, see “Work With Rin Kamo: Science Writing & Biomedical Content Support.”.


    References

    Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6(10):a016295. doi:10.1101/cshperspect.a016295. PMID:25190079.

    Castell JV, Gómez-Lechón MJ, David M, Andus T, Geiger T, Trullenque R, et al. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett. 1989;242(2):237-239. doi:10.1016/0014-5793(89)80476-4. PMID:2464504.

    Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. Front Immunol. 2018;9:754. doi:10.3389/fimmu.2018.00754. PMID:29706967.

    Ridker PM. From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. Circ Res. 2016;118(1):145-156. doi:10.1161/CIRCRESAHA.115.306656. PMID:26837745.

    Ridker PM, MacFadyen JG, Glynn RJ, Bradwin G, Hasan AA, Rifai N. Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial. Eur Heart J. 2020;41(31):2952-2961. doi:10.1093/eurheartj/ehaa160. PMID:32221587.

    Mehta NN, deGoma E, Shapiro MD. IL-6 and cardiovascular risk: a narrative review. Curr Atheroscler Rep. 2025;27:12. doi:10.1007/s11883-024-01259-7. PMID:39589436. PMCID:PMC11599326.

    Zeng F, Huang Y, Guo Y, Yin M, Chen X, Xiao L, et al. Association of inflammatory markers with the severity of COVID-19: a meta-analysis. Int J Infect Dis. 2020;96:467-474. doi:10.1016/j.ijid.2020.05.055. PMID:32425643.

    Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol. 2007;49(21):2129-2138. doi:10.1016/j.jacc.2007.02.052. PMID:17531663.

    Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342(12):836-843. doi:10.1056/NEJM200003233421202. PMID:10733371.

    Ji P, Zhu J, Zhong Z, Li H, Pang J, Li B, et al. Association of elevated inflammatory markers and severe COVID-19: a meta-analysis. Medicine (Baltimore). 2020;99(47):e23315. doi:10.1097/MD.0000000000023315. PMID:33217868. PMCID:PMC7676531.

    Samprathi M, Jayashree M. Biomarkers in COVID-19: An Up-To-Date Review. Front Pediatr. 2021;8:607647. doi:10.3389/fped.2020.607647. PMID:33859967. PMCID:PMC8042162.

    Bivona G, Agnello L, Ciaccio M. Biomarkers for Prognosis and Treatment Response in COVID-19 Patients. Ann Lab Med. 2021;41(6):540-548. doi:10.3343/alm.2021.41.6.540. PMID:34108281. PMCID:PMC8203437.

    Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111(12):1805-1812. doi:10.1172/JCI18921. PMID:12813013.

    Markanday A. Acute phase reactants in infections: evidence-based review and a guide for clinicians. Open Forum Infect Dis. 2015;2(3):ofv098. doi:10.1093/ofid/ofv098. PMID:26258155. PMCID:PMC4525013.

    Lee EH, Lee KH, Song YG, Han SH. Discrepancy of C-reactive protein, procalcitonin and interleukin-6 at hospitalization: infection in patients with normal C-reactive protein, procalcitonin and high interleukin-6 values. J Clin Med. 2022;11(24):7324. doi:10.3390/jcm11247324. PMID:36555941. PMCID:PMC9783053.

    Tocu G, Mihailov R, Serban C, Stefanescu BI, Tutunaru D, Firescu D. The contribution of procalcitonin, C-reactive protein and interleukin-6 in the diagnosis and prognosis of surgical sepsis: an observational and statistical study. J Multidiscip Healthc. 2023;16:2351-2359. doi:10.2147/JMDH.S422359. PMID:37601324. PMCID:PMC10439796.

    Singh B, Goyal A, Patel BC. C-reactive protein: clinical relevance and interpretation. [Updated 2025 May 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan- [cited 2026 Aug 16]. PMID:28722873.

    Lee Y, McKechnie T, Doumouras AG, Handler C, Eskicioglu C, Gmora S, et al. Diagnostic value of C-reactive protein levels in postoperative infectious complications after bariatric surgery: a systematic review and meta-analysis. Obes Surg. 2019;29(7):2022-2029. doi:10.1007/s11695-019-03832-5. PMID:30895509.

    Devaraj S, Singh U, Jialal I. Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol. 2009;20(3):182-189. doi:10.1097/MOL.0b013e32832ac03e. PMID:19369869. PMCID:PMC2921825.

    Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282(22):2131-2135. doi:10.1001/jama.282.22.2131. PMID:10591334.

    Ishii S, Karlamangla AS, Bote M, Irwin MR, Jacobs DR Jr, Cho HJ, et al. Gender, obesity and repeated elevation of C-reactive protein: data from the CARDIA cohort. PLoS One. 2012;7(4):e36062. doi:10.1371/journal.pone.0036062. PMID:22558327. PMCID:PMC3340402.

    Wener MH, Daum PR, McQuillan GM. The influence of age, sex, and race on the upper reference limit of serum C-reactive protein concentration. J Rheumatol. 2000;27(10):2351-2359. PMID:11036829.

    Randall ZD, Brouillard AM, Deych E, Rich MW. Demographic, behavioral, dietary, and clinical predictors of high-sensitivity C-reactive protein: the National Health and Nutrition Examination Surveys (NHANES). Am Heart J Plus. 2022;21:100196. doi:10.1016/j.ahjo.2022.100196. PMID:38559751. PMCID:PMC10978421.

    Dockree S, Brook J, James T, Shine B, Impey L, Vatish M. Pregnancy-specific reference intervals for C-reactive protein improve diagnostic accuracy for infection: a longitudinal study. Clin Chim Acta. 2021;517:81-85. doi:10.1016/j.cca.2021.02.015. PMID:33647266.

    Stec-Martyna E, Wojtczak K, Nowak D, Stawski R. Battle of the biomarkers of systemic inflammation. Biology (Basel). 2025;14(4):438. doi:10.3390/biology14040438. PMID:40282303. PMCID:PMC12024891.

    MedlinePlus. C-reactive protein (CRP) test [Internet]. Bethesda (MD): National Library of Medicine (US); 2025 Jun 11 [cited 2026 Jul 15].

    Centola M, Cavet G, Shen Y, Ramanujan S, Knowlton N, Swan KA, et al. Development of a multi-biomarker disease activity test for rheumatoid arthritis. PLoS One. 2013;8(4):e60635. doi:10.1371/journal.pone.0060635. PMID:23585841. PMCID:PMC3621826.

    Reiss WG, Devenport JN, Low JM, Wu G, Sasso EH. Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis. Rheumatol Int. 2016;36(2):295-300. doi:10.1007/s00296-015-3285-2. PMID:26026604. PMCID:PMC4723630.

    Sorić Hosman I, Kos I, Lamot L. Serum amyloid A in inflammatory rheumatic diseases: a compendious review of a renowned biomarker. Front Immunol. 2021;11:631299. doi:10.3389/fimmu.2020.631299. PMID:33679725. PMCID:PMC7933664.

    Ziegler L, Lundström A, Havervall S, Thålin C, Gigante B. IL-6 signalling biomarkers in hospitalised patients with moderate to severe SARS-CoV-2 infection in a single centre study in Sweden. Cytokine. 2022;159:156020. doi:10.1016/j.cyto.2022.156020. PMID:36057230. PMCID:PMC9420722.

    Hung SK, Lan HM, Han ST, Wu CC, Chen KF. Current evidence and limitation of biomarkers for detecting sepsis and systemic infection. Biomedicines. 2020;8(11):494. doi:10.3390/biomedicines8110494. PMID:33198109. PMCID:PMC7697922.


     
     
    賀茂 琳(Kamo Rin)|医学博士/免疫・がん・分子生物学 最新のPubMed論文を基盤に、IL-6を中心とするサイトカイン研究を“高頻度アップデート型”で解説しています。 専門性を保ちつつ、医療者・研究者・学生が実務で使える“理解の手がかり”を届けたいです。

    あなたへのおすすめ